Author:
Belum Viswanath Reddy,Wu Shenhong,Lacouture Mario E.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference31 articles.
1. Regorafenib [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2013 (accessed from: http://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdf , on March 17, 2013)
2. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Regorafenib. Available from http://www.clinicaltrials.gov/ct2/results?term=regorafenib&Search=Search [accessed on Mar 20, 2013]
3. Frost A, Buechert M, Unger C et al (2008) Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: final results of a dose-escalation study. J Clin Oncol 26:126 (suppl; abstr 2558)
4. Kies MS, Blumenschein GRJ, Christensen O, Lin T, Tolcher AW (2010) Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC). J Clin Oncol 28:15 (suppl; abstr 7585)
5. Bolondi L, Tak WY, Gasbarrini A, Santoro A (2011) Phase II safety study of the oral multikinase inhibitor regorafenib (BAY 73-4506) as second-line therapy in patients with hepatocellular carcinoma. Eur J Cancer 47(Supplement 1):S464
Cited by
81 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献